Cong, E. | Li, Y. | Shao, C. | Chen, J. | Wu, W. | Shang, X. | Wang, Z. | Liu, Y. | Liu, L. | Gao, C. | Li, Y. | Wu, J. | Deng, H. | Liu, J. | Sang, W. | Liu, G. | Rong, H. | Gan, Z. | Li, L. | Li, K. | Pan, J. | Li, Y. | Cui, Y. | Sun, L. | Liu, L. | Liu, H. | Zhao, X. | Zhang, Y. | Zhang, R. | Chen, Y. | Wang, X. | Li, H. | Chen, Y. | Lin, Y. | Kendler, K. S. | Flint, J. | Shi, S.
Background
Studies in Western countries have repeatedly shown that women with a history of childhood sexual abuse (CSA) are at increased risk for developing major depression (MD). Would this relationship be found in China?
Method
Three levels of CSA (non-genital, genital, and intercourse) were assessed by self-report in two groups of Han Chinese women: 1970 clinically ascertained with recurrent MD and 2597 matched controls. Diagnostic and other risk factor information was assessed at personal interview. Odds ratios (ORs) were calculated by logistic regression and regression coefficients by linear or Poisson regression.
Results
Any form of CSA was significantly associated with recurrent MD [OR 3.26, 95% confidence interval (CI) 1.95–5.45]. This association strengthened with increasing CSA severity: non-genital (OR 2.47, 95% CI 1.17–5.23), genital (OR 2.77, 95% CI 1.32–5.83) and intercourse (OR 13.35, 95% CI 1.83–97.42). The association between any form of CSA and MD remained significant after accounting for parental history of depression, childhood emotional neglect (CEN), childhood physical abuse (CPA) and parent–child relationship. Among the depressed women, those with CSA had an earlier age of onset, longer depressive episodes and an increased risk for generalized anxiety disorder (GAD; OR 1.92, 95% CI 1.39–2.66) and dysthymia (OR 2.16, 95% CI 1.52–3.09).
Conclusions
In Chinese women CSA is strongly associated with MD and this association increases with greater severity of CSA. Depressed women with CSA have an earlier age of onset, longer depressive episodes and increased co-morbidity with GAD and dysthymia. Although reporting biases cannot be ruled out, our results are consistent with the hypothesis that, as in Western countries, CSA substantially increases the risk for MD in China.
doi:10.1017/S0033291711001462
PMCID: PMC3250087
PMID: 21835095
Childhood sexual abuse; co-morbidity; major depression
The Ets transcription factor, Fli-1 is activated in murine erythroleukemia and overexpressed in various human malignancies including Ewing's sarcoma, induced by the oncogenic fusion protein EWS/Fli-1. Recent studies by our group and others have demonstrated that Fli-1 plays a key role in tumorigenesis, and disrupting its oncogenic function may serve as a potential treatment option for malignancies associated with its overexpression. Herein, we describe the discovery of 30 anti-Fli-1 compounds, characterized into six functional groups. Treatment of murine and human leukemic cell lines with select compounds inhibits Fli-1 protein or mRNA expression, resulting in proliferation arrest and apoptosis. This anti-cancer effect was mediated, at least in part through direct inhibition of Fli-1 function, as anti-Fli-1 drug treatment inhibited Fli-1 DNA binding to target genes, such as SHIP-1 and gata-1, governing hematopoietic differentiation and proliferation. Furthermore, treatment with select Fli-1 inhibitors revealed a positive relationship between the loss of DNA-binding activity and Fli-1 phosphorylation. Accordingly, anti-Fli-1 drug treatment significantly inhibited leukemogenesis in a murine erythroleukemia model overexpressing Fli-1. This study demonstrates the ability of this drug-screening strategy to isolate effective anti-Fli-1 inhibitors and highlights their potential use for the treatment of malignancies overexpressing this oncogene.
doi:10.1038/bcj.2011.52
PMCID: PMC3270256
PMID: 22829238
erythroleukemia; Fli-1; drug inhibition
Einarsdóttir, K | Darabi, H | Czene, K | Li, Y | Low, Y L | Li, Y Q | Bonnard, C | Wedrén, S | Liu, E T | Hall, P | Liu, J | Humphreys, K
We investigated common genetic variation in the entire ESR1 and EGF genes in relation to endometrial cancer risk, myometrial invasion and endometrial cancer survival. We genotyped a dense set of single-nucleotide polymorphisms (SNPs) in both genes and selected haplotype tagging SNPs (tagSNPs). The tagSNPs were genotyped in 713 Swedish endometrial cancer cases and 1567 population controls and the results incorporated into logistic regression and Cox proportional hazards models. We found five adjacent tagSNPs covering a region of 15 kb at the 5′ end of ESR1 that decreased the endometrial cancer risk. The ESR1 variants did not, however, seem to affect myometrial invasion or endometrial cancer survival. For the EGF gene, no association emerged between common genetic variants and endometrial cancer risk or myometrial invasion, but we found a five-tagSNP region that covered 51 kb at the 5′ end of the gene where all five tagSNPs seemed to decrease the risk of dying from endometrial cancer. One of the five tagSNPs in this region was in strong linkage disequilibrium (LD) with the untranslated A61G (rs4444903) EGF variant, earlier shown to be associated with risk for other forms of cancer.
doi:10.1038/sj.bjc.6604984
PMCID: PMC2676544
PMID: 19319135
ESR1; EGF; polymorphism; endometrial cancer; survival
Alcoholic liver disease (ALD) is a major cause of morbidity and mortality worldwide. The spectrum of ALD ranges from fatty liver to alcoholic hepatitis and cirrhosis, which may eventually lead to the development of hepatocellular carcinoma. In developed countries as well as many developing nations, ALD is a major cause of end-stage liver disease that requires liver transplantation. The most effective therapy for ALD is alcohol abstinence; however, for individuals with severe forms of ALD and those in whom alcohol abstinence is not achievable, targeted therapies are absolutely necessary. In this context, advances of our understanding of the pathophysiology of ALD over the past two decades have contributed to the development of therapeutic modalities (e.g., pentoxifylline and corticosteroids) for the disease though the efficacy of the available treatments remains limited. This article is intended to succinctly review the recent experimental and clinical findings regarding the involvement of oxidative stress and redox signaling in the pathophysiology of ALD and the development of mechanistically-based antioxidant modalities to target the oxidative stress and redox signaling mechanisms of ALD. The biochemical and cellular sources of reactive oxygen and nitrogen species (ROS/RNS) and the dysregulated redox signaling pathways associated with alcohol consumption are particularly discussed to provide insight into the molecular basis of hepatic cell dysfunction and destruction as well as tissue remodeling underlying ALD.
doi:10.1111/j.1751-2980.2011.00569.x
PMCID: PMC3297983
PMID: 22356308
alcoholic liver disease; oxidative stress; redox signaling; inflammation; antioxidants
doi:10.3747/pdi.2011.00162
PMCID: PMC3525405
PMID: 22383732
Turner syndrome; renal failure; dialysis modality
Mouton, P.R. | Kelley-Bell, B. | Tweedie, D. | Spangler, E.L | Perez, E. | Carlson, O.D. | Short, R.G. | deCabo, R. | Chang, J. | Ingram, D.K. | Li, Y. | Greig, N.H.
Parkinson’s disease (PD), an age-related movement disorder, is characterized by severe catecholaminergic neuron loss in the substantia nigra pars compacta-ventral tegmental area (SNPC-VTA) and locus coeruleus (LC). To assess the stability of these central catecholaminergic neurons following an acute episode of severe inflammation, 6 to 22 month-old C57/Bl6 mice received a maximally tolerated dose of LPS followed by euthanasia two hours later to assay peak levels of peripheral and central cytokines; and, 14 weeks later for computerized stereology of tyrosine hydroxylase-immunopositive (TH+) neurons in the SNPC-VTA and LC. Two hours after LPS, cytokine levels varied in an age-related manner, with the greatest peripheral and central elevations in old and young mice, respectively. Severe inflammation failed to cause loss of TH+ neurons in SNPC-VTA or LC; however, there was an age-related decline in these TH+ neurons in LPS-treated and control groups. Thus, unknown mechanisms in the B6 mouse brain appear to protect against catecholaminergic neuron loss during an acute episode of severe inflammation, while catecholaminergic neuron loss occurs during normal aging.
doi:10.1016/j.neurobiolaging.2010.09.025
PMCID: PMC3116956
PMID: 21093964
Age-related Neuron Loss; Parkinsonism; Neuroinflammation; Computerized stereology; Stereologer; Substantia nigra; Ventral Tegmental Area
Kawamura, S | Sato, I | Wada, T | Yamaguchi, K | Li, Y | Li, D | Zhao, X | Ueno, S | Aoki, H | Tochigi, T | Kuwahara, M | Kitamura, T | Takahashi, K | Moriya, S | Miyagi, T
Prostate cancers generally become androgen-independent and resistant to hormone therapy with progression. To understand the underlying mechanisms and facilitate the development of novel treatments for androgen-independent prostate cancer, we have investigated plasma membrane-associated sialidase (NEU3), the key enzyme for ganglioside hydrolysis participating in transmembrane signaling. We have discovered NEU3 to be upregulated in human prostate cancer compared with non-cancerous tissue, correlating with the Gleason score. NEU3 silencing with siRNA in prostate cancer PC-3 and LNCaP cells resulted in increased expression of differentiation markers and in cell apoptosis, but decrease in Bcl-2 as well as a progression-related transcription factor, early growth response gene (EGR-1). In androgen-sensitive LNCaP cells, forced overexpression of NEU3 significantly induced expression of EGR-1, androgen receptor (AR) and PSA both with and without androgen, the cells becoming sensitive to androgen. The NEU3-mediated induction was abrogated by inhibitors for PI-3 kinase and MAP kinase and more specifically by their silencing in the absence of androgen, being confirmed by increased phosphorylation of AKT and ERK1/2 in NEU3 overexpressing cells. NEU3 siRNA introduction caused reduction of cell growth of an androgen-independent PC-3 cells in culture and of transplanted tumors in nude mice. These data suggest that NEU3 regulates tumor progression through AR signaling, and thus be a potential tool for diagnosis and therapy of androgen-independent prostate cancer.
doi:10.1038/cdd.2011.83
PMCID: PMC3252839
PMID: 21681193
sialidase; prostate cancer; androgen receptor; EGR-1; PSA
Background
Genomic testing for common genetic variants associated with skin cancer risk could enable personalized risk feedback to motivate skin cancer screening and sun protection.
Methods
In a cross-sectional study, we investigated whether skin cancer cognitions and behavioral factors, sociodemographics, family factors, and health information-seeking were related to perceived importance of learning about how (a) genes and (b) health habits affect personal health risks using classification and regression trees (CART).
Results
The sample (n = 1,772) was collected in a large health maintenance organization as part of the Multiplex Initiative, ranged in age from 25–40, was 53% female, 41% Caucasian, and 59% African-American. Most reported that they placed somewhat to very high importance on learning about how genes (79%) and health habits (88%) affect their health risks. Social influence actors were associated with information-seeking about genes and health habits. Awareness of family history was associated with importance of health habit, but not genetic, information-seeking.
Conclusions
The investment of family and friends in health promotion may be a primary motivator for prioritizing information-seeking about how genes and health habits affect personal health risks and may contribute to the personal value, or personal utility, of risk information. Individuals who seek such risk information may be receptive to interventions aimed to maximize the social implications of healthy lifestyle change to reduce their health risks.
doi:10.1159/000330403
PMCID: PMC3318939
PMID: 21921576
Genetic information; Skin cancer concerns
Zhang, X | Reis, M | Khoriaty, R | Li, Y | Ouillette, P | Samayoa, J | Carter, H | Karchin, R | Li, M | Diaz, LA | Velculescu, VE | Papadopoulos, N | Kinzler, KW | Vogelstein, B | Malek, SN
doi:10.1038/leu.2011.163
PMCID: PMC3523306
PMID: 21701494
Eye
2011;25(12):1581-1589.
Purpose
Aniridia (AN) is a rare congenital panocular disorder caused by the mutations of the paired box homeotic gene 6(PAX6) gene. The PAX6gene is also involved in other anterior segment malformations including Peters anomaly. We studied the PAX6gene mutations in a cohort of affected individuals with different clinical phenotype including AN, coloboma of iris and choroid, or anterior segment malformations.
Patients and methods
Six unrelated families and 10 sporadic patients were examined clinically. After informed consent was obtained, genomic DNA was extracted from the venous blood of all participants. Mutation screening of all exons of the PAX6gene was performed by direct sequencing of PCR-amplified DNA fragments. Multiplex ligation-dependent probe amplification (MLPA) was performed to detect large deletions.
Results
By clinical examination, the patients and the pedigrees were divided into the following three groups: AN, coloboma of iris and choroids, and the anterior segment malformations including peters anomaly. Sequencing of the PAX6gene, three intragenic mutations including a novel heterozygous splicing-site mutations c.357-3C>G (p.Ser119fsX) were identified in the patients of the AN group. A novel missense mutation c.643T>C (p.S216P) was detected in the anterior segment malformation group. The mutation p.S216P located in the homeodomain region of the PAX6 caused the phenotype of Peters anomaly in family A6 with different expressing. Through MLPA analysis, a large deletion including the whole PAX6gene and DKFZ p686k1684gene was detected in one sporadic patient from the AN group. Neither intragenic mutation nor large deletion was identified in the group with coloboma of iris and choroid.
Conclusion
Our findings further confirmed that different kind of mutations might cause different ocular phenotype, and clearly clinical phenotype classification might increase the mutation detection rate of the PAX6gene.
doi:10.1038/eye.2011.215
PMCID: PMC3234463
PMID: 21904390
aniridia; PAX6 gene; mutation; Peters anomaly
Summary
The anatomical complexity of the paraclinoid region has made surgical treatment of intracranial ophthalmic segment aneurysms (OSAs) difficult. This study evaluated the safety and efficacy of endovascular treatment of paraclinoid aneurysms. We conducted a retrospective study of 28 patients with 30 aneurysms of the paraclinoid in whom treatment with endovascular techniques was attempted. Patient age, sex, presence of subarachnoid hemorrhage, aneurysm type, size of aneurismal sac and treatment modality were reviewed. Clinical evaluation and control angiography were performed between one and 43 months. Overall, complete occlusion was obtained in 26 aneurysms (86.6%), nearly complete (>90%) occlusion in two aneurysms (6.7%) and incomplete occlusion was observed in two aneurysms (6.7%). All endovascular techniques were successful. Procedure-related complications were observed in two patients (7.1%). Patients underwent follow-up for a mean of 14.8 months (range 1-43 months). Repeated coil treatment was performed in one patient. One patient died of massive brain infarction six days postoperatively and thus no follow-up data were available for this case. In 27 patients with follow-up studies, aneurysm closure was complete in 22 (81.5%) and incomplete in five (18.5%). Endovascular treatment is a safe and efficient alternative approach for paraclinoid aneurysms.
PMCID: PMC3296501
PMID: 22192545
aneurysm, embolization, internal carotid artery, paraclinoid
Li, Y. | van der Lee, T. A. J. | Evenhuis, A. | van den Bosch, G. B. M. | van Bekkum, P. J. | Förch, M. G. | van Gent-Pelzer, M. P. E | van Raaij, H. M. G. | Jacobsen, E. | Huang, S. W. | Govers, F. | Vleeshouwers, V. G. A. A. | Kessel, G. J. T.
For a comprehensive survey of the structure and dynamics of the Dutch Phytophthora infestans population, 652 P. infestans isolates were collected from commercial potato fields in the Netherlands during the 10-year period 2000–2009. Genotyping was performed using 12 highly informative microsatellite markers and mitochondrial haplotypes. In addition, for each isolate, the mating type was determined. STRUCTURE analysis grouped the 322 identified genotypes in three clusters. Cluster 1 consists of a single clonal lineage NL-001, known as “Blue_13”; all isolates in this cluster have the A2 mating type and the Ia mitochondrial haplotype. Clusters 2 and 3 display a more elaborate substructure containing many unique genotypes. In Cluster 3, several distinct clonal lineages were also identified. This survey witnesses that the Dutch population underwent dramatic changes in the 10 years under study. The most notable change was the emergence and spread of A2 mating type strain NL-001 (or “Blue_13”). The results emphasize the importance of the sexual cycle in generating genetic diversity and the importance of the asexual cycle as the propagation and dispersal mechanism for successful genotypes. Isolates were also screened for absence of the Avrblb1/ipiO class I gene, which is indicative for virulence on Rpi-blb1. This is also the first report of Rpi-blb1 breakers in the Netherlands. Superimposing the virulence screening on the SSR genetic backbone indicates that lack the Avrblb1/ipiO class I gene only occurred in sexual progeny. So far, the asexual spread of the virulent isolates identified has been limited.
doi:10.1534/g3.112.004150
PMCID: PMC3516475
PMID: 23275876
late blight; Blue_13; avirulence; microsatellites; population genetics
Background
The study evaluated efficacy and safety of the 2 mg dose of prucalopride compared to placebo in patients with chronic constipation (CC) from the Asia-Pacific region.
Methods
Randomized, placebo-controlled, parallel-group, phase III study with 2-week run-in, 12-week treatment phase, and 1-week follow-up. Adult patients with CC (≤2 spontaneous bowel movements per week) received 2 mg prucalopride or placebo, once-daily, for 12 weeks. Primary efficacy measure was percentage of patients with average of ≥3 spontaneous complete bowel movements (SCBMs) per week (Responders) during the 12-week treatment. A key secondary endpoint was Responders during first 4 weeks of treatment. Other efficacy assessments were based on patient diaries, their assessments of symptoms and quality of life, and investigator’s assessment on efficacy of treatment. Safety assessments included adverse events, laboratory values, and cardiovascular events.
Key Results
Efficacy and safety were evaluated for 501 patients who received study drug. On the primary endpoint, prucalopride was significantly more effective than placebo with 83 (33.3%) vs 26 (10.3%) patients having a weekly average of ≥3 SCBMs during the 12-week treatment (P < 0.001). Respective percentages were 34.5%vs 11.1% over first 4 weeks (P < 0.001). On other secondary endpoints, clinical improvement was generally larger and statistically superior (P < 0.001) in the prucalopride group. Most frequently reported adverse events were diarrhea, nausea, abdominal pain, and headache.
Conclusion & Inferences
Prucalopride 2 mg given once-daily significantly improved bowel function, associated symptoms, and satisfaction in CC over a 12-week treatment period, and was safe and well tolerated by patients in the Asia-Pacific region.
doi:10.1111/j.1365-2982.2012.01983.x
PMCID: PMC3509366
PMID: 22882724
Asian; Asia-Pacific; constipation; efficacy; prucalopride; safety
Albrechtsen, A. | Grarup, N. | Li, Y. | Sparsø, T. | Tian, G. | Cao, H. | Jiang, T. | Kim, S. Y. | Korneliussen, T. | Li, Q. | Nie, C. | Wu, R. | Skotte, L. | Morris, A. P. | Ladenvall, C. | Cauchi, S. | Stančáková, A. | Andersen, G. | Astrup, A. | Banasik, K. | Bennett, A. J. | Bolund, L. | Charpentier, G. | Chen, Y. | Dekker, J. M. | Doney, A. S. F. | Dorkhan, M. | Forsen, T. | Frayling, T. M. | Groves, C. J. | Gui, Y. | Hallmans, G. | Hattersley, A. T. | He, K. | Hitman, G. A. | Holmkvist, J. | Huang, S. | Jiang, H. | Jin, X. | Justesen, J. M. | Kristiansen, K. | Kuusisto, J. | Lajer, M. | Lantieri, O. | Li, W. | Liang, H. | Liao, Q. | Liu, X. | Ma, T. | Ma, X. | Manijak, M. P. | Marre, M. | Mokrosiński, J. | Morris, A. D. | Mu, B. | Nielsen, A. A. | Nijpels, G. | Nilsson, P. | Palmer, C. N. A. | Rayner, N. W. | Renström, F. | Ribel-Madsen, R. | Robertson, N. | Rolandsson, O. | Rossing, P. | Schwartz, T. W. | Slagboom, P. E. | Sterner, M. | Tang, M. | Tarnow, L. | Tuomi, T. | van’t Riet, E. | van Leeuwen, N. | Varga, T. V. | Vestmar, M. A. | Walker, M. | Wang, B. | Wang, Y. | Wu, H. | Xi, F. | Yengo, L. | Yu, C. | Zhang, X. | Zhang, J. | Zhang, Q. | Zhang, W. | Zheng, H. | Zhou, Y. | Altshuler, D. | ‘t Hart, L. M. | Franks, P. W. | Balkau, B. | Froguel, P. | McCarthy, M. I. | Laakso, M. | Groop, L. | Christensen, C. | Brandslund, I. | Lauritzen, T. | Witte, D. R. | Linneberg, A. | Jørgensen, T. | Hansen, T. | Wang, J. | Nielsen, R. | Pedersen, O.
Aims/hypothesis
Human complex metabolic traits are in part regulated by genetic determinants. Here we applied exome sequencing to identify novel associations of coding polymorphisms at minor allele frequencies (MAFs) >1% with common metabolic phenotypes.
Methods
The study comprised three stages. We performed medium-depth (8×) whole exome sequencing in 1,000 cases with type 2 diabetes, BMI >27.5 kg/m2 and hypertension and in 1,000 controls (stage 1). We selected 16,192 polymorphisms nominally associated (p < 0.05) with case–control status, from four selected annotation categories or from loci reported to associate with metabolic traits. These variants were genotyped in 15,989 Danes to search for association with 12 metabolic phenotypes (stage 2). In stage 3, polymorphisms showing potential associations were genotyped in a further 63,896 Europeans.
Results
Exome sequencing identified 70,182 polymorphisms with MAF >1%. In stage 2 we identified 51 potential associations with one or more of eight metabolic phenotypes covered by 45 unique polymorphisms. In meta-analyses of stage 2 and stage 3 results, we demonstrated robust associations for coding polymorphisms in CD300LG (fasting HDL-cholesterol: MAF 3.5%, p = 8.5 × 10−14), COBLL1 (type 2 diabetes: MAF 12.5%, OR 0.88, p = 1.2 × 10−11) and MACF1 (type 2 diabetes: MAF 23.4%, OR 1.10, p = 8.2 × 10−10).
Conclusions/interpretation
We applied exome sequencing as a basis for finding genetic determinants of metabolic traits and show the existence of low-frequency and common coding polymorphisms with impact on common metabolic traits. Based on our study, coding polymorphisms with MAF above 1% do not seem to have particularly high effect sizes on the measured metabolic traits.
Electronic supplementary material
The online version of this article (doi:10.1007/s00125-012-2756-1) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
doi:10.1007/s00125-012-2756-1
PMCID: PMC3536959
PMID: 23160641
Exome sequencing; Genetic epidemiology; Genetics; Lipids; Next-generation sequencing; Obesity; Type 2 diabetes
doi:10.1186/cc11757
PMCID: PMC3504871
Xu, G | Wang, Z | Li, Y | Li, Z | Tang, H | Zhao, J | Xiang, X | Ding, L | Ma, L | Yuan, F | Fei, J | Wang, W | Wang, N | Guan, Y | Tang, C | Mulholland, M | Zhang, W
Aims/hypothesis
Rapamycin impaired glucose tolerance and insulin sensitivity. Our previous study demonstrated that rapamycin significantly increases the expression of gastric ghrelin, which is critical in the regulation of glucose metabolism. Here, we investigated whether ghrelin contributes to derangements of glucose metabolism induced by rapamycin.
Methods
The effects of rapamycin on glucose metabolism were examined in mice receiving ghrelin receptor antagonist or with ghrelin receptor gene deletion. Changes in Glut4, JNK, and pS6 were investigated by immnuofluorescent staining or Western. Related hormones were detected by radioimmuno-assay kits.
Results
Rapamycin impaired glucose metabolism and insulin sensitivity not only in normal C57BL/6J mice but also in both obese mice induced by high fat diet and db/db mice. This was accompanied by elevation of plasma acylated ghrelin. Rapamycin significantly increased the levels of plasma acylated ghrelin in normal C57BL/6J mice, high fat diet induced obese mice, and db/db mice. Elevation in plasma acylated ghrelin and derangements of glucose metabolism upon administration of rapamycin was significantly correlated. The deterioration in glucose homeostasis induced by rapamycin was blocked by D-Lys3-GHRP-6, a ghrelin receptor antagonist, or by deletion of ghrelin receptor gene. Ghrelin receptor antagonism and ghrelin receptor gene deletion blocked the up-regulation of JNK activity, and GLUT4 expression and translocation in the gastrocnemius muscle induced by rapamycin.
Conclusions
The current study demonstrates that ghrelin contributes to derangements of glucose metabolism induced by rapamycin via altering the expression and translocation of GLUT4 in muscles.
doi:10.1007/s00125-012-2509-1
PMCID: PMC3496261
PMID: 22391948
Ghrelin; glucose metabolism; rapamycin
Pugach, M.K. | Ozer, F. | Li, Y. | Sheth, K. | Beasley, R. | Resnick, A. | Daneshmehr, L. | Kulkarni, A.B. | Bartlett, J.D. | Gibson, C.W. | Lindemeyer, R.G.
Patients with amelogenesis imperfecta (AI) have defective enamel; therefore, bonded restorations of patients with AI have variable success rates. To distinguish which cases of AI may have good clinical outcomes with bonded materials, we evaluated etching characteristics and bond strength of enamel in mouse models, comparing wild-type (WT) with those having mutations in amelogenin (Amelx) and matrix metalloproteinase-20 (Mmp20), which mimic 2 forms of human AI. Etched enamel surfaces were compared for roughness by scanning electron microscopy (SEM) images. Bonding was compared through shear bond strength (SBS) studies with 2 different systems (etch-and-rinse and self-etch). Etched enamel surfaces of incisors from Amelx knock-out (AmelxKO) mice appeared randomly organized and non-uniform compared with WT. Etching of Mmp20KO surfaces left little enamel, and the etching pattern was indistinguishable from unetched surfaces. SBS results were significantly different when AmelxKO and Mmp20KO enamel surfaces were compared. A significant increase in SBS was measured for all samples when the self-etch system was compared with the etch-and-rinse system. We have developed a novel system for testing shear bond strength of mouse incisors with AI variants, and analysis of these data may have important clinical implications for the treatment of patients with AI.
doi:10.1177/0022034511421929
PMCID: PMC3188463
PMID: 21917602
enamel; acid-etching; amelogenesis imperfecta; shear bond strength; amelogenin; matrix metalloproteinase-20
Motivation: The area under the receiver operating characteristic (ROC) curve (AUC), long regarded as a ‘golden’ measure for the predictiveness of a continuous score, has propelled the need to develop AUC-based predictors. However, the AUC-based ensemble methods are rather scant, largely due to the fact that the associated objective function is neither continuous nor concave. Indeed, there is no reliable numerical algorithm identifying optimal combination of a set of biomarkers to maximize the AUC, especially when the number of biomarkers is large.
Results: We have proposed a novel AUC-based statistical ensemble methods for combining multiple biomarkers to differentiate a binary response of interest. Specifically, we propose to replace the non-continuous and non-convex AUC objective function by a convex surrogate loss function, whose minimizer can be efficiently identified. With the established framework, the lasso and other regularization techniques enable feature selections. Extensive simulations have demonstrated the superiority of the new methods to the existing methods. The proposal has been applied to a gene expression dataset to construct gene expression scores to differentiate elderly women with low bone mineral density (BMD) and those with normal BMD. The AUCs of the resulting scores in the independent test dataset has been satisfactory.
Conclusion: Aiming for directly maximizing AUC, the proposed AUC-based ensemble method provides an efficient means of generating a stable combination of multiple biomarkers, which is especially useful under the high-dimensional settings.
Contact: lutian@stanford.edu
Supplementary Information: Supplementary data are available at Bioinformatics online.
doi:10.1093/bioinformatics/btr516
PMCID: PMC3198577
PMID: 21908541
Introduction
Anemia in burn patients is due to surgical blood loss and anemia of critical illness. Since the commitment paradigm of common bone marrow progenitors dictates the production of erythroid, myeloid, and lymphoid cells, we hypothesized that skewed bone marrow lineage commitment decreases red cell production and causes anemia after a burn injury.
Methods
After anesthesia, B6D2F1 mice received a 15% TBSA dorsal scald burn. The sham group did not receive scald burn. Femoral bone marrow was harvested on 2, 5, 7, 14 and 21 days post burn (PBD). Total bone marrow cells were labeled with specific antibodies to erythroid (CD71/Ter119), myeloid (CD11b), and lymphoid (CD19) lineages and analyzed by flowcytometry. To test whether erythropoietin (EPO) could increase red blood cell production, EPO was administered to sham and burn animals and their reticulocyte response was measured on PBD#2 and PBD#7.
Results
Burn injury reduced the erythroid cells of the bone marrow from 35% in sham to 17% by PBD#5 and remained at similar level until PBD#21. Myeloid cells however, increased from 42% in sham to 60% on PBD #5 and 77% on PBD#21. Burn injury reduced reticulocyte counts on PBD#2 and PBD#7 indicating that the erythroid compartment is severely depleted. This depleted compartment however responded to EPO but was not sufficient to change red cell production.
Conclusion
Burn injury skews the bone marrow hematopoietic commitment away from erythroid and toward myeloid cells. Shrinkage of the erythroid compartment contributes to resistance to EPO and the anemia of critical illness.
doi:10.1097/TA.0b013e31822e2803
PMCID: PMC3217199
PMID: 22071930
Apoptosis has a vital role in maintaining tissue homeostasis, and dysregulation of the apoptotic pathway is now widely recognized as a key step in tumourigenesis. Increasingly, evidence has demonstrated that microRNA (miRNA) can exert various biological functions in tumours by targeting oncogenes or tumour suppressors. Nevertheless, the role of miRNA in apoptosis remains unclear. Here we show that ectopical expression of miR-148a can induce apoptosis in colorectal cancer cells. In addition, MYB can inhibit miR-148a by directly acting on the transcription factor binding site in miR-148a gene and miR-148a can posttranscriptionally silence Bcl-2. Subsequently, the intrinsic apoptosis pathway is activated by releasing cytochrome c, cleaving caspase 9, caspase 3 and PARP, which eventually induce cancer-cell apoptosis. These findings are part of a hitherto undocumented apoptotic regulatory pathway in which a pleiotropic transcription factor controls the expression of a miRNA and the miRNA inhibits the target, leading to activation of an intrinsic mitochondrial pathway and tumour apoptosis.
doi:10.1038/cdd.2011.28
PMCID: PMC3190106
PMID: 21455217
colorectal cancer; miR-148a; apoptosis; Bcl-2
Li, Y | Shaw, C A | Sheffer, I | Sule, N | Powell, S Z | Dawson, B | Zaidi, S N Y | Bucasas, K L | Lupski, J R | Wilhelmsen, K C | Doody, R | Szigeti, K
Genetic variation, both single-nucleotide variations and copy number variations (CNV), contribute to changes in gene expression. In some cases these variations are meaningfully correlated with disease states. We hypothesized that in a genetically heterogeneous disorder such as sporadic Alzheimer's disease (AD), utilizing gene expression as a quantitative trait and CNVs as a genetic marker map within the same individuals in the context of case–control status may increase the power to detect relevant loci. Using this approach an 8-kb deletion was identified that contains a PAX6-binding site on chr2q33.3 upstream of CREB1 encoding the cAMP responsive element-binding protein1 transcription factor. The association of the CNV to AD was confirmed by a case–control association study consisting of the Texas Alzheimer Research and Care Consortium and NIA-LOAD Family Study data sets.
doi:10.1038/tp.2012.119
PMCID: PMC3565761
PMID: 23168992
Alzheimer's disease; eQTL; multi-omics
Sjögren’s syndrome (SS) is an autoimmune disease targeting the exocrine glands resulting in xerostomia/keratoconjunctivitis sicca. Presently, we examined the levels and clinical correlations of IL-22 in SS. Patients with SS together with normal controls were randomly selected. IL-22 was detected at significantly higher levels in sera of patients with SS. The levels of IL-22 present in sera showed statistically significant direct correlations with hyposalivation, anti-SSB, anti-SSA/SSB combined, hypergammaglobulinemia and rheumatoid factor. IL-22 showed a direct correlation with major clinical parameters. The data suggest that IL-22 plays a critical role in the development of SS, and further study is needed to examine its function in human SS.
doi:10.1111/j.1365-3083.2011.02583.x
PMCID: PMC3250060
PMID: 21645026
Theis, JF | de Parseval, A | Honnen, WJ | Phogat, A | Ganapathi, UC | Lai, Z | Peng, L | Reichman, C | Moore, PL | Morris, L | Li, Y | Hu, S | Pinter, A
doi:10.1186/1742-4690-9-S2-P28
PMCID: PMC3441856
Georgiev, I | Acharya, P | Schmidt, SD | Li, Y | Wycuff, D | Ofek, G | Doria-Rose, N | Luongo, TS | Yang, Y | Zhou, T | Donald, BR | Mascola, JR | Kwong, PD
doi:10.1186/1742-4690-9-S2-P50
PMCID: PMC3442034
Li, Y | O’Dell, S | Wilson, R | Wu, X | Schmidt, SD | Hogerkorp, C | Louder, MK | Longo, N | Poulsen, C | Guenaga, J | Chakrabarti, B | Doria-Rose, N | Roederer, M | Connors, M | Mascola, JR | Wyatt, RT
doi:10.1186/1742-4690-9-S2-P99
PMCID: PMC3442062